Skip to Main Content

Paper Details

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
Investigational New Drugs
59
2020
AMG, AMG 232, BC, DDLPS, ER+, GBM, MDM2, MDM2-overexpressing ER, MM, OST, P53, P53 wild-type solid tumors, P53WT, TP53, WDLPS, advanced solid tumors, anemia, breast cancer, cytopenias, decreased appetite, diarrhea, fatigue, glioblastoma multiforme, human, multiple myeloma, nausea, neutropenia, p53, patients, serum macrophage inhibitor cytokine-1, solid tumors, thrombocytopenia, vomiting
Author NameAffiliation
David S SiegelJohn Theurer Cancer Center at the Hackensack University Medical Center
  • 1 - 1

Datasets

Release 1.2